Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VIVUS Inc (NASDAQ:VVUS)

1.20
Delayed Data
As of 3:59pm ET
 -0.04 / -3.23%
Today’s Change
0.92
Today|||52-Week Range
2.25
+17.65%
Year-to-Date
GW Pharma Attains 52-Week High on Positive Epidiolex Data
9:44am / Zacks.com - Paid Partner Content
Teva Reports Positive Phase III Tardive Dyskinesia Data
Sep 23 / Zacks.com - Paid Partner Content
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps
Sep 26 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close1.24
Today’s open1.24
Day’s range1.18 - 1.32
Volume780,288
Average volume (3 months)542,521
Market cap$129.2M
Dividend yield--
Data as of 3:59pm ET, 09/27/2016

Growth & Valuation

Earnings growth (last year)-12.50%
Earnings growth (this year)+18.52%
Earnings growth (next 5 years)+0.84%
Revenue growth (last year)-16.42%
P/E ratioNM
Price/Sales1.11
Price/Book--

Competitors

 Today’s
change
Today’s
% change
ZYNEZynerba Pharmaceutic...-0.23-1.64%
NVLSNivalis Therapeutics...+0.02+0.24%
ANTHAnthera Pharmaceutic...+0.09+2.85%
ADHDAlcobra Ltd+0.02+0.44%
Data as of 4:00pm ET, 09/27/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$95.4M
Annual profit (last year)-$93.1M
Net profit margin-97.57%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Director
Seth H. Z. Fischer
Chief Financial &
Accounting Officer
Mark K. Oki
Corporate headquarters
Mountain View, California

Forecasts

Search for Jobs